A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.

Autor: Toledano-Fonseca M; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain; Cancer Network Biomedical Research Center (CIBERONC), Instituto de Salud Carlos III, E28029 Madrid, Spain. Electronic address: martatoledanofonseca@gmail.com., Gómez-España MA; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain; Department of Medical Oncology, Reina Sofía University Hospital, E14004 Córdoba, Spain. Electronic address: magespanya@hotmail.com., Élez E; Department of Medical Oncology, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119, 08035 Barcelona, Spain. Electronic address: meelez@vhio.net., Grávalos C; Department of Medical Oncology, H. Universitario 12 de Octubre, Instituto de Investigación i+12, Avenida de Córdoba, S/N, 28041 Madrid, Spain. Electronic address: cristina.gravalos@salud.madrid.org., García-Alfonso P; Department of Medical Oncology, H. Gregorio Marañón, Calle del Doctor Esquerdo, 46, 28007 Madrid, Spain. Electronic address: pgarcaalfonso@gmail.com., Rodríguez R; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain; Department of Medical Oncology, Reina Sofía University Hospital, E14004 Córdoba, Spain. Electronic address: rosarodriguezalonso@gmail.com., Losa F; Department of Medical Oncology, ICO-CSI. H. Sant Joan Despí - Moisés Broggi, Carrer d'Oriol Martorell, 12, 08970 Sant Joan Despí, Barcelona, Spain. Electronic address: ferran.losa@sanitatintegral.org., Alés Díaz I; Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica. Hospitales Universitarios Regional y Virgen de la Victoria. IBIMA, Campus de Teatinos, S/N, 29010 Málaga, Spain. Electronic address: inales@hotmail.com., Graña B; Department of Medical Oncology, C. H. Universitario, Lugar, Xubias de Arriba, 84, 15006 A Coruña, Spain. Electronic address: Begona.Grana.Suarez@sergas.es., Valladares-Ayerbes M; Department of Medical Oncology, H. Virgen del Rocío, IBIS, Av. Manuel Siurot s/n, 41013 Sevilla, Spain. Electronic address: mvalaye@icloud.com., García-Ortiz MV; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain; Cancer Network Biomedical Research Center (CIBERONC), Instituto de Salud Carlos III, E28029 Madrid, Spain. Electronic address: mvictoria.garcia@imibic.org., Polo E; Department of Medical Oncology, H. Miguel Servet, Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain. Electronic address: eduardopolomarques@hotmail.com., Salgado M; Department of Medical Oncology, C. H. Universitario de Ourense, Calle Ramón Puga Noguerol, 54, 32005 Orense, Spain. Electronic address: mercedes.salgado.fernandez@sergas.es., Rivera F; Department of Medical Oncology, H. Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, 25, 39008 Santander, Spain. Electronic address: oncrhf@humv.es., Safont MJ; Department of Medical Oncology, H. General Universitario, CIBERONC, Universidad de Valencia, Avenida de les Tres Creus, 2, 46014 Valencia, Spain. Electronic address: mjsafont@yahoo.es., Salud A; Department of Medical Oncology, H. Universitario Arnau de Vilanova, Avenida Alcalde Rovira Roure, 80, 25198 Lérida, Spain. Electronic address: asaluds@hotmail.com., Ruiz-Casado A; Department of Medical Oncology, H. Puerta de Hierro Majadahonda, Calle Joaquín Rodrigo, 1, 28222 Majadahonda, Spain. Electronic address: ruizcasado@yahoo.com., Tabernero JM; Department of Medical Oncology, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119, 08035 Barcelona, Spain. Electronic address: jtabernero@vhio.net., Riesco MC; Department of Medical Oncology, H. Universitario 12 de Octubre, Instituto de Investigación i+12, Avenida de Córdoba, S/N, 28041 Madrid, Spain. Electronic address: m.carmen.riesco@gmail.com., Rodríguez-Ariza A; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain; Cancer Network Biomedical Research Center (CIBERONC), Instituto de Salud Carlos III, E28029 Madrid, Spain; Department of Medical Oncology, Reina Sofía University Hospital, E14004 Córdoba, Spain. Electronic address: antonio.rodriguez.exts@juntadeandalucia.es., Aranda E; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, Spain; Cancer Network Biomedical Research Center (CIBERONC), Instituto de Salud Carlos III, E28029 Madrid, Spain; Department of Medical Oncology, Reina Sofía University Hospital, E14004 Córdoba, Spain; Department of Medicine, Faculty of Medicine, University of Córdoba, E14004 Córdoba, Spain. Electronic address: earandaa@seom.org.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Mar; Vol. 159, pp. 114272. Date of Electronic Publication: 2023 Jan 25.
DOI: 10.1016/j.biopha.2023.114272
Abstrakt: The benefit of adding the antiangiogenic drug aflibercept to FOLFIRI regime in metastatic colorectal cancer (CRC) patients resistant to or progressive on an oxaliplatin-based therapy has been previously demonstrated. However, the absence of validated biomarkers to predict greater outcomes is a major challenge encountered when using antiangiogenic therapies. In this study we investigated profiles of circulating microRNAs (miRNAs) to build predictive models of response to treatment and survival. Plasma was obtained from 98 metastatic CRC patients enrolled in a clinical phase II trial before receiving FOLFIRI plus aflibercept treatment, and the circulating levels of 754 individual miRNAs were quantified using real-time PCR. A distinct signature of circulating miRNAs differentiated responder from non-responder patients. Remarkably, most of these miRNAs were found to target genes that are involved in angiogenic processes. Accordingly, some of these miRNAs had predictive value and entered in predictive models of response to therapy, progression of disease, and survival of patients treated with FOLFIRI plus aflibercept. Among these miRNAs, circulating levels of hsa-miR-33b-5p efficiently discriminated between responder and non-responder patients and predicted the risk of disease progression. Moreover, the combination of circulating VEGF-A and miR-33b-5p levels improved clinical stratification of metastatic CRC patients who were to receive FOLFIRI plus aflibercept treatment. In conclusion, our study supports circulating miRNAs as valuable biomarkers for predicting better outcomes in metastatic CRC patients treated with FOLFIRI plus aflibercept.
Competing Interests: Conflict of interest statement María Auxiliadora Gómez-España reports Grants or contracts to Maimonides Biomedical Research Institute of Córdoba (IMIBIC) from Alianza mixta en red de Andalucía-Roche en Oncología Médica de precisión, Consejería De Salud and support for attending meetings and/or travel from AMGEN, MERCK, ROCHE, SANOFI, SERVIER, BAYER, PIERRE FABRE. M. Valladares reports personal fees from SANOFI, grants or contracts from ROCHE, AMGEN, consulting fees from MERCK, AMGEN, SERVIER, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ROCHE, MERCK, AMGEN, SERVIER, BAYER, CELGENE and support for attending meetings and/or travel from ROCHE, MERCK, AMGEN, SERVIER. Mª J. Safont reports consulting fees from MERCK, AMGEN, SANOFI, SERVIER, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from MERCK, AMGEN, SANOFI, SERVIER, PIERRE FABRE, BMS, MSD, payment for expert testimony from MERCK, AMGEN, SANOFI, SERVIER, PIERRE FABRE, support for attending meetings and/or travel from MERCK, AMGEN and participation on a Data Safety Monitoring Board or Advisory Board from AMGEN. A. Ruiz Casado reports consulting fees from SANOFI, SERVIER, BAYER, PIERRE FABRE, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ABBOTT, AMGEN, LILLY and support for attending meetings and/or travel from AMGEN. E. Aranda has received honoraria for advisory role from AMGEN, BAYER, BMS, MERCK, ROCHE, SANOFI. The other authors have stated that they have no conflicts of interest.
(Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: